Part of our global strategy is the use for long-term care of the entire list of 170 pathogens from parasites (soil transmitted helminths (STHs), Plasmodium species) and viruses (respiratory syncytial virus, influenza, human metapneumovirus, human bocavirus, and HIV) to bacteria (Mycobacterium tuberculosis, Salmonella, and methicillin-resistant Staphylococcus aureus). The additional research we have conducted as part of this process has been designed with societies needs in mind and to build a long-term future for this company rather than the modern ‘microwave’ approach that rarely reaps long term results.
We are serious in our approach to delivering an on-time and essential product and to be a valued and influential player in the business community with a reputation for being a focused yet diverse, dynamic and pioneering business venture. It is our vision to build and operate a professional company that earns its striped as a respected member of the Med/Pharma business community.
After detailed research and careful analysis, our pricing is based on conversations with influencers from various fields and markets, from medical, pharma, ECOM, BnM business and consumers and more.